GS
ALLO icon

GTS Securities’s Allogene Therapeutics ALLO Stock Holding History

GTS Securities’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5K Buy
+13,220
New +$29K ﹤0.01% 1288
2023
Q4 		– Sell
-10,994
Closed -$34.9K – 4007
2023
Q3 		$34.9K Buy
+10,994
New +$48.2K ﹤0.01% 3751

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GTS Securities's ALLO Position: Q2 2026 in Review

GTS Securities opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 13,220 shares worth $27.5K. The stake represents ﹤0.01% of the portfolio and ranks #1288 among its holdings. This is a return to the name: GTS Securities previously reported a position in ALLO as recently as Q3 2023.

GTS Securities first reported a position in ALLO in Q3 2023 and has held it in 2 quarters since. The position peaked at $34.9K in Q3 2023. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • GTS Securities held 13,220 shares of Allogene Therapeutics worth $27.5K as of Q2 2026.
  • Allogene Therapeutics was a new GTS Securities position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1288 holding.
  • GTS Securities first reported a position in Allogene Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • GTS Securities's Allogene Therapeutics position peaked at $34.9K in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.